Phase 4 N=42 Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)
Heart Failure
Primary: Change in Peak VO2 (Oxygen Consumption ) — 1.21; 0.48 ml/kg/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=45 Ext. Long-term Safety Study in CF Patients: Single Arm TIP
Long-term Safety of TIP
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs/SAEs Leading to Discontinuation of Study Drug and Deaths Over 12 Treatment Cycles…
Phase 4 N=7 Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.
Barrett's Esophagus · Esophageal Cancer
Primary: Depth of Injury — 4.0; 5.2 millimeters
Phase 4 N=50 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema
Diabetic Macular Edema
Primary: Mean Visual Acuity Change — 5.6; 5.8 ETDRS letters
Phase 4 N=65 Duloxetine for Chronic Depression: a Double-blind Study
Dysthymic Disorder · Depressive Disorder NOS
Primary: Hamilton Depression Rating Scale (HDRS) - 24 Total Score — 5; 10 Scores on a scale — p=.003
Phase 4 N=29 Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression
Bipolar Depression
Primary: Change in 17-item Hamilton Depression Rating Scale From Baseline to 8 Weeks (Baseline - 8 Wks) — 7; 9 units on a scale
Phase 4 N=50 Low Level Laser Treatment and Breast Cancer Related Lymphedema
Lymphedema
Primary: LDex Change- — 28.0; 17.8; 22.2 LDex
Phase 4 N=150 Comparison of Efficacy and Tolerability of Two Cough Syrups in Cough Due to Cold in Children.
Cough · Upper Respiratory Tract Infection
Primary: Change in Night Cough Score on First Night of Treatment (From N0 to N1) — -5.16; -1.77 change in combined night cough score — p=<0.01
Phase 4 N=54 Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia
Idiopathic Scoliosis · Spondylolisthesis
Primary: Morphine Equivalent Consumption (mg/kg) — 1.3; 1.36; 1.28; 1.275 mg/kg
Phase 4 N=1,945 Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)
Chronic Obstructive Pulmonary Disease
Primary: Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year — 0.805; 0.927 exacerbations per patient per year — p=0.0529
Phase 4 N=145 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS
Rheumatoid Arthritis
Primary: Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score at Week 24 in Intent-to-treat (ITT) Population — 21.2; 5.4 units on a…
Phase 4 N=665 Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence
Opioid Dependence, on Agonist Therapy
Primary: Number of Patients Reporting Treatment-Emergent Adverse Events — 20; 21 participants
Phase 4 N=150 A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization
Benign Prostatic Hyperplasia
Primary: Percentage of Participants With Treatment Success — 84.9 percentage of participants
Phase 4 N=70 A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia
Anemia
Primary: Change From Baseline in Mean Hb Concentration at Week 20 — 8.820; 1.440 Grams per deciliter (gm/dL) — p=<0.0001
Phase 4 N=89 Effect of Nebulized Bronchodilators on Heart Rate
COPD · Sepsis · Shock
Primary: Heart Rate in Beats Per Minute — -0.16; 1.40 bpm — p=0.01